The global life sciences sector has witnessed significant advances in the development and manufacturing of Antibody-Drug Conjugates (ADCs), a class of targeted cancer therapies that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs. [1][2]In this landscape, Wuxi AppTec and its former subsidiary, WuXi Biologics, have played integral roles in advancing pharmaceutical innovation, particularly in ADCs.
WuXi AppTec, established as a contract research and manufacturing organization, laid the groundwork for integrated drug development services in China. In 2010, WuXi Biologics was founded as the biologics division of WuXi AppTec, focusing on the discovery, development, and manufacturing of biologics, including ADCs. The 2017 corporate spin-off made WuXi Biologics an independent, publicly traded entity, although the two companies continue to share a closely linked history, leadership, and operational collaborations. This shared legacy has contributed to a robust infrastructure for biopharmaceutical development and manufacturing, making Wuxi a recognized name in the sector.
Both WuXi AppTec and WuXi Biologics have contributed to the growth of ADC manufacturing capabilities, offering end-to-end solutions for global pharmaceutical and biotechnology companies. Their capacity to integrate complex biomanufacturing processes, coupled with their operational scale and technical expertise, has made them key players in the ADC supply chain. Through joint ventures and specialized projects, such as WuXi XDC, these companies provide services ranging from antibody production to payload synthesis and conjugation, supporting the growing global demand for targeted cancer therapies.
A highly complex global supply chain
The development and manufacturing of drugs such as antibody-drug conjugates involve a highly complex global supply chain, with multiple steps—ranging from early research and discovery to process development, scale-up, and fill-finish—that often occur in different countries. Cross-border technology transfers between Western and Chinese companies, in particular, have become increasingly intricate due to China’s role in ADC innovation and evolving regulatory landscapes in both regions. [3].
These transactions are shaped by several key factors: stringent technology export controls imposed by the Chinese Ministry of Commerce (MOFCOM), Western legislative oversight to protect supply chains and intellectual property, and the use of complex corporate structures or joint ventures to navigate regulatory requirements. Additionally, the transfer of clinical and manufacturing data is governed by robust data localization and privacy laws, requiring compliance with both Chinese and international frameworks. Additionally, the transfer of clinical and manufacturing data is governed by robust data localization and privacy laws, requiring compliance with both Chinese and international frameworks.
Operational Challenges
Chemistry, manufacturing, and controls (CMC) translation between Chinese and Western partners is a highly specialized process that presents operational challenges, particularly for highly potent payloads and combination products.[4] Adding licensing agreements to this mix of technology transfers between Chinese and Western companies, itself a notoriously complex process, compounded by strict cross-border export controls, rigid contract registration, and deeply divergent legal frameworks, further significantly affects development timelines. [5]
Overall, the international nature of these supply chains reflects both the collaborative opportunities and operational challenges inherent in delivering advanced therapies to a global patient population.
Supply chain security
Despite the advancements made, WuXi AppTec has drawn attention from regulatory and legislative bodies, particularly regarding international supply chain security and foreign biotechnology providers. In February 2024, the U.S. House Select Committee on the Chinese Communist Party sent a letter to the Administration requesting a formal investigation into WuXi AppTec, expressing concerns about national security and supply chain risks. [5]
Subsequent actions by U.S. government agencies included labeling WuXi AppTec as a Chinese military company, further intensifying scrutiny and debate. [6]
In response, WuXi AppTec, in an open letter to customers, has publicly stated its commitment to compliance with applicable laws and international standards, disputing allegations and highlighting its role in supporting global pharmaceutical clients. [7] These developments underscore the complex interplay among global healthcare innovation, regulatory scrutiny, and geopolitical factors shaping the future of ADC development and manufacturing.
The evolving status of WuXi AppTec highlights broader questions about how international collaboration and competition influence access to advanced medical technologies. As the ADC sector continues to grow, stakeholders across the industry, including developers, manufacturers, and regulators, will need to navigate these dynamics to ensure the continued advancement of targeted therapies for patients worldwide.
Reference
[1] Olivier, K. J., Jr., & Hurvitz, S. A. (Eds.). (2023). Antibody-Drug Conjugates: Fundamentals, Drug Development, and Clinical Outcomes to Target Cancer. 1st ed. Hoboken, NJ: Wiley. Available at: https://amzn.to/4eDrMOg
[2] Dong W, Wang W, Cao C. The Evolution of Antibody-Drug Conjugates: Toward Accurate DAR and Multi-specificity. ChemMedChem. 2024 Sep 2;19(17):e202400109. doi: 10.1002/cmdc.202400109. Epub 2024 Jul 2. PMID: 38758596.
[3] Liao T and Valenstein CA. US-China Biotech Transactions: Navigating Each Country’s Evolving Regulatory Landscape. Online. Last accessed in June 2026.
[4] Sliwoski, H., and Harris, D. China Technology Licensing: A Comprehensive Guide. Lexology. Online.
[5] Final letter from the U.S. House Select Committee dated 2.12.24 regarding WuXi AppTec. Online. Last accessed in June 2026.
[6] Slabodkin G. DoD’s labeling of WuXi AppTec as a Chinese military company causes ‘irreparable’ harm. Pharma Manufacturing June 18, 2026, Online. Last accessed in June 2026.
[7] An Open Letter to Customers. WuXi AppTec. June 8, 2026. Online. Last accessed in June 2026.
Featured image © 2026 Sunvalley Communication. Used with permission.
DOI
